To determine the effect of midazolam on ketamine-xylazine anesthesia, 20 guinea fowl (Numida meleagris galeata) were randomly divided into 2 groups. Birds in group KX were anesthetized with ketamine (15 mg/kg IM) and xylazine (2.5 mg/kg IM), whereas the birds anesthetized in group KXM received midazolam (0.3 mg/kg IM) in addition to the ketamine and xylazine protocol. The onset of anesthesia, duration of analgesia, duration of recumbency, and recovery time were determined. Heart and respiratory rates as well as cloacal temperatures were recorded immediately after drug administration and at 10-minute intervals until the birds were sternally recumbent. Analgesia was assessed as a response to artery forceps applied to the digit and skin proximal to the tarsal joint. The mean (SD) duration of analgesia in the group KXM birds was 37.4 ± 23.5 minutes, whereas no analgesia was apparent with the group KX birds. The duration of recumbency was significantly longer and respiratory rates were significantly lower in group KXM birds compared with those in group KX. Adverse effects were minimal and included diarrhea (n = 1) and hypersalivation (n = 2) in group KX birds, and regurgitation (n = 2) in group KXM birds. Midazolam administered intramuscularly appeared to improve the anesthetic quality of ketamine and xylazine in guinea fowls without adversely affecting safety.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 23 • No. 3